Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Brandýs nad Labem, České Budějovice, Chlumec Nad Cidlinou Iv, Havířov, Jilove U Prahy, Krnov, Ostrava, Poštovní, Prague, Praha 1, and Praha 6, CzechiaSee the 14 sites
- Phase
- Phase 3
Where in Czechia
- Diacentrum Brandys n.L. s.r.o.Brandýs nad Labem, CzechiaTaking people
- KardioInt s.r.o. Lékařský dům GéčkoČeské Budějovice, CzechiaTaking people
- MUDr. Alena Váchová Diabetologie a obezitologieČeské Budějovice, CzechiaTaking people
- Kardio Chlumec s.r.o.Chlumec Nad Cidlinou Iv, CzechiaTaking people
- DIKa centrum s.r.o.Havířov, CzechiaTaking people
- Diavital Jesenice s.r.o.Jilove U Prahy, CzechiaTaking people
- MUDr. Tomas Edelsberger DiabetologieKrnov, CzechiaTaking people
- MUDr. Miroslav Koliba s.r.o.Ostrava, CzechiaTaking people
- Kardiologie KarMa s.r.o.Poštovní, CzechiaTaking people
- Centrum kardiovaskularni mediciny s.r.o.Prague, CzechiaTaking people
- MILAN KVAPIL s.r.o.Prague, CzechiaTaking people
- Praglandia s.r.o.Prague, CzechiaTaking people
- MUDr. Jana Parkanyiová Endokrinologie a diabetologiePraha 1, CzechiaTaking people
- Diabetologie a endokrinologie, J.Venerová s.r.o.Praha 6, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.